FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966851131> ?p ?o ?g. }

• W1966851131 endingPage "4147" @default.
• W1966851131 startingPage "4139" @default.
• W1966851131 abstract "The miR-106b-25 microRNA (miRNA) cluster is a candidate oncogene in human prostate cancer. Here, we report that miRNAs encoded by miR-106b-25 are upregulated in both primary tumors and distant metastasis. Moreover, increased tumor miR-106b expression was associated with disease recurrence and the combination of high miR-106b and low CASP7 (caspase-7) expressions in primary tumors was an independent predictor of early disease recurrence (adjusted hazard ratio=4.1; 95% confidence interval: 1.6–12.3). To identify yet unknown oncogenic functions of miR-106b, we overexpressed it in LNCaP human prostate cancer cells to examine miR-106b-induced global expression changes among protein-coding genes. The approach revealed that CASP7 is a direct target of miR-106b, which was confirmed by western blot analysis and a 3′-untranslated region reporter assay. Moreover, selected phenotypes induced by miR-106b knockdown in DU145 human prostate cancer cells did not develop when both miR-106b and CASP7 expression were inhibited. Further analyses showed that CASP7 is downregulated in primary prostate tumors and metastatic lesions across multiple data sets and is by itself associated with disease recurrence and disease-specific survival. Using bioinformatics, we also observed that miR-106b-25 may specifically influence focal adhesion-related pathways. This observation was experimentally examined using miR-106b-25-transduced 22Rv1 human prostate cancer cells. After infection with a miR-106b-25 lentiviral expression construct, 22Rv1 cells showed increased adhesion to basement membrane- and bone matrix-related filaments and enhanced soft agar growth. In summary, miR-106b-25 was found to be associated with prostate cancer progression and disease outcome and may do so by altering apoptosis- and focal adhesion-related pathways." @default.
• W1966851131 created "2016-06-24" @default.
• W1966851131 creator A5002886067 @default.
• W1966851131 creator A5011782043 @default.
• W1966851131 creator A5017672961 @default.
• W1966851131 creator A5023820565 @default.
• W1966851131 creator A5032870776 @default.
• W1966851131 creator A5045151033 @default.
• W1966851131 creator A5053591052 @default.
• W1966851131 creator A5060450409 @default.
• W1966851131 creator A5063851986 @default.
• W1966851131 creator A5069506234 @default.
• W1966851131 creator A5070319506 @default.
• W1966851131 creator A5079700663 @default.
• W1966851131 creator A5091148741 @default.
• W1966851131 date "2012-09-17" @default.
• W1966851131 modified "2023-10-07" @default.
• W1966851131 title "MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer" @default.
• W1966851131 cites W1648301895 @default.
• W1966851131 cites W1965371218 @default.
• W1966851131 cites W1967342065 @default.
• W1966851131 cites W1967832728 @default.
• W1966851131 cites W1981298542 @default.
• W1966851131 cites W1983428971 @default.
• W1966851131 cites W1983821491 @default.
• W1966851131 cites W1984409810 @default.
• W1966851131 cites W1988163167 @default.
• W1966851131 cites W2004588189 @default.
• W1966851131 cites W2010057554 @default.
• W1966851131 cites W2012141576 @default.
• W1966851131 cites W2040182688 @default.
• W1966851131 cites W2053702192 @default.
• W1966851131 cites W2062290101 @default.
• W1966851131 cites W2065735233 @default.
• W1966851131 cites W2070297079 @default.
• W1966851131 cites W2078210863 @default.
• W1966851131 cites W2078576279 @default.
• W1966851131 cites W2093557716 @default.
• W1966851131 cites W2096528675 @default.
• W1966851131 cites W2100975741 @default.
• W1966851131 cites W2105613536 @default.
• W1966851131 cites W2107633226 @default.
• W1966851131 cites W2115094397 @default.
• W1966851131 cites W2121629705 @default.
• W1966851131 cites W2131456432 @default.
• W1966851131 cites W2135314242 @default.
• W1966851131 cites W2137751769 @default.
• W1966851131 cites W2144038313 @default.
• W1966851131 cites W2144154026 @default.
• W1966851131 cites W2151201664 @default.
• W1966851131 cites W2151834630 @default.
• W1966851131 cites W2157968886 @default.
• W1966851131 cites W2158216140 @default.
• W1966851131 doi "https://doi.org/10.1038/onc.2012.424" @default.
• W1966851131 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3530025" @default.
• W1966851131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22986525" @default.
• W1966851131 hasPublicationYear "2012" @default.
• W1966851131 type Work @default.
• W1966851131 sameAs 1966851131 @default.
• W1966851131 citedByCount "105" @default.
• W1966851131 countsByYear W19668511312013 @default.
• W1966851131 countsByYear W19668511312014 @default.
• W1966851131 countsByYear W19668511312015 @default.
• W1966851131 countsByYear W19668511312016 @default.
• W1966851131 countsByYear W19668511312017 @default.
• W1966851131 countsByYear W19668511312018 @default.
• W1966851131 countsByYear W19668511312019 @default.
• W1966851131 countsByYear W19668511312020 @default.
• W1966851131 countsByYear W19668511312021 @default.
• W1966851131 countsByYear W19668511312022 @default.
• W1966851131 countsByYear W19668511312023 @default.
• W1966851131 crossrefType "journal-article" @default.
• W1966851131 hasAuthorship W1966851131A5002886067 @default.
• W1966851131 hasAuthorship W1966851131A5011782043 @default.
• W1966851131 hasAuthorship W1966851131A5017672961 @default.
• W1966851131 hasAuthorship W1966851131A5023820565 @default.
• W1966851131 hasAuthorship W1966851131A5032870776 @default.
• W1966851131 hasAuthorship W1966851131A5045151033 @default.
• W1966851131 hasAuthorship W1966851131A5053591052 @default.
• W1966851131 hasAuthorship W1966851131A5060450409 @default.
• W1966851131 hasAuthorship W1966851131A5063851986 @default.
• W1966851131 hasAuthorship W1966851131A5069506234 @default.
• W1966851131 hasAuthorship W1966851131A5070319506 @default.
• W1966851131 hasAuthorship W1966851131A5079700663 @default.
• W1966851131 hasAuthorship W1966851131A5091148741 @default.
• W1966851131 hasBestOaLocation W19668511311 @default.
• W1966851131 hasConcept C104317684 @default.
• W1966851131 hasConcept C121608353 @default.
• W1966851131 hasConcept C142724271 @default.
• W1966851131 hasConcept C145059251 @default.
• W1966851131 hasConcept C2776438761 @default.
• W1966851131 hasConcept C2779013556 @default.
• W1966851131 hasConcept C2779723316 @default.
• W1966851131 hasConcept C2780192828 @default.
• W1966851131 hasConcept C2781018059 @default.
• W1966851131 hasConcept C29537977 @default.
• W1966851131 hasConcept C502942594 @default.
• W1966851131 hasConcept C54355233 @default.

• next